Marizomib

Marizomib (Salinosporamide A) is a second-generation, irreversible, brain-penetrant, pan-proteasome inhibitor. Marizomib inhibits the CT-L (β5), CT-T-laspase-like (C-L, β1) and trypsin-like (T-L, β2) activities of the 20S proteasome (IC50=3.5, 28, and 430 nM, respectively) [1][2][3].

Product Specifications

CAS Number

[437742-34-2]

Product Name Alternative

Salinosporamide A; NPI-0052

UNSPSC

12352005

Hazard Statement

H315, H361, H372

Target

Proteasome

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Marizomib.html

Purity

99.13

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C([C@H](CCCl)[C@]1(C)O2)N[C@@]1([C@H]([C@@H]3C=CCCC3)O)C2=O

Molecular Formula

C15H20ClNO4

Molecular Weight

313.78

Precautions

H315, H361, H372

References & Citations

[1]Di K, et al. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brainbarrier. Neuro Oncol. 2016 Jun;18 (6) :840-8.|[2]Kale AJ, et al. Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem. 2012 Dec 13;55 (23) :10317-27.|[3]Singh AV, et al. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol. 2010 May;149 (4) :550-9.